Cilengitide
From Wikipedia, the free encyclopedia
| Cilengitide | |
|---|---|
 |
|
| Identifiers | |
| CAS number | [188968-51-6] |
| PubChem | |
| MeSH | |
| Properties | |
| Molecular formula | C27H40N8O7 |
| Molar mass | 588.656 g/mol |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) Infobox disclaimer and references |
|
Cilengitide is a molecule designed and synthesized at the Technical University Munich in collaboration with Merck KGaA in Darmstadt. It is based on the cyclic peptide cyclo(-RGDfV-), which is selective for αv integrines, which are important in angiogenesis (forming new blood vessels). Hence, it is investigated for treating cancer by inhibiting angiogenesis.[1][2]
[edit] References
- ^ Burke P, DeNardo S, Miers L, Lamborn K, Matzku S, DeNardo G (2002). "Cilengitide targeting of αvβ3 integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts". Cancer Res 62 (15): 4263–72. PMID 12154028.
- ^ Goodman Simon L., Hoelzemann Guenter, Sulyok Gabor A. G., Kessler Horst (2002). "Nanomolar Small Molecule Inhibitors for αvβ6, αvβ5, and αvβ3 Integrins". Journal of Medicinal Chemistry 45 (5): 1045–51. doi:. PMID 11855984.
 |
This article about an organic compound is a stub. You can help Wikipedia by expanding it. |
